Press Releases

 Filter by Provider

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL --

LONG BEACH, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2026 (“Q1 2026”).

HAMILTON, Bermuda, May 07, 2026 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT), a specialty underwriter, today announced results for its first quarter ended March 31, 2026.

LITTLE ROCK, Ark., May 07, 2026 (GLOBE NEWSWIRE) -- Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the first quarter ended March 31, 2026.

— Strong Top-Line Growth and Solid Profitability —

Total Revenue of $55.3 Million

Revenue Up 54% Year-Over-Year, Beats Consensus by 18%

CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026.

VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the first quarter March 31, 2026 and provided a summary of recent business highlights.

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data

– Total Revenues increased 35.3% for the quarter over the prior year period to $72.8 million –– Organic Revenue Growth Rate* of 10.1% for the quarter –– Net income of $13.1 million for the quarter –– Adjusted EBITDA* increased 73.9% for the quarter over the prior year period to $21.2 million -– $40 million Shares Repurchased from Authorized plan for up to $50 million -

SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the first quarter ending March 31, 2026, and provided a corporate update.

LONG BEACH, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today shared the financial results for fiscal first quarter ended March 31, 2026.

First quarter SaaS revenue of $93.4 million, representing 35% year-over-year growth, 29% on a constant currency basisFirst quarter Total revenue of $117.2 million, representing 26% year-over-year growth, 20% on a constant currency basisTotal ARR of $435.2 million, representing 26% year-over-year growth, 23% adjusted for FX

– Quarterly results marked by 104% revenue growth and improved operating performance –

Delivered Total and Net Investment Income of $29.5 million and $10.6 million, Respectively

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life.

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis

Company delivered strong topline growth, improved operating cash flow, and accelerated growth in trailing 12-month Active Buyers

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) --

The Adelaide-based cosmetic dentist is celebrating 40 years in business, delivering personalised cosmetic and implant dentistry. The team specialises in advanced solutions like All on X and full mouth implants alongside long-term dental care specific to the individual needs of the patient.

Founding partner Ross Andrews says professionals should prioritise structured tax debt management after July 2025 ATO changes made GIC and SIC non-deductible.

Founder Ahmed Shabana describes a future where companies operate like autonomous CEO agents and clarifies misconceptions around government contract execution

Dropbox, Inc. (NASDAQ: DBX) today announced financial results for its first quarter ended March 31, 2026.

Revenue up 42% Year over Year; Total Members Surpass One Million;Expanded Channels Now Include All Three of the Nation’s Leading PBMs

FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand, today announced a long-term partnership with Noah Wyle, Emmy-award winning executive producer and actor. Together, FIGS and Wyle will work to address the most urgent challenges facing the healthcare workforce — including fair compensation, mental health support, workplace safety and administrative burden.

Launches OASYS as the gold standard agentic platform to revolutionize the way businesses interact with customers across every channel and touchpoint

Cardlytics, Inc. (NASDAQ: CDLX), a commerce media platform, today announced financial results for the first quarter ended March 31, 2026.

Warner Music Group Corp. today announced its second-quarter financial results for the period ended March 31, 2026.

HA Sustainable Infrastructure Capital, Inc. (“HASI”) (NYSE: HASI), a leading investor in sustainable infrastructure assets, and KKR, a leading global investment firm, today announced that CarbonCount Holdings 1 LLC (“CCH1”), a co-investment vehicle between HASI and KKR, has issued $508 million in aggregate principal amount of senior unsecured notes (the “Notes”) in a private offering. The fixed-rate amortizing notes will have a 20-year final maturity. The Notes were priced at a weighted average coupon of 6.29%. These Notes represent the second issuance of senior notes by CCH1, following its inaugural issuance in June 2025, which priced at a weighted-average coupon of 6.76%.

SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31, 2026.

- American Place Casino Revenues Increased 7.1%, Reflecting Continued Momentum in the First Quarter

The Company will Report First Quarter 2026 Financial Results on May 11, 2026

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that its Board of Directors has declared a quarterly dividend of $0.07 per share. The cash dividend will be paid on June 17, 2026, to shareholders of record as of the close of business on June 3, 2026.

JACKSONVILLE, FL / ACCESS Newswire / May 7, 2026 / ParkerVision, Inc. (OTCQB:PRKR) ("ParkerVision" or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for the three months ended March 31, 2026.

Forward Air Corporation (NASDAQ:FWRD) (the “Company”, “Forward”, “we”, “our”, or “us”) today reported financial results for the three months ended March 31, 2026, as presented in the tables below.

Perdoceo Education Corporation (NASDAQ: PRDO), a provider of postsecondary education programs through its academic institutions, today reported operating and financial results for the first quarter ended March 31, 2026.

Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) today reported financial results for the first quarter of 2026.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal data from the ongoing Phase 1/2a open-label extension (OLE) studies that provide additional support for zorevunersen as a potential disease-modifying treatment for Dravet syndrome. Statistically significant improvements were demonstrated in cognition and behavior at 1, 2, 3 and 4 years of treatment compared to OLE baseline. Reductions in major motor seizure frequency were observed through 4 years of treatment in patients taking standard anti-seizure medicines (ASMs). Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress.

Power Integrations (NASDAQ: POWI) today announced financial results for the quarter ended March 31, 2026. Net revenue for the first quarter was $108.3 million, up five percent from the prior quarter and up three percent from the first quarter of 2025. GAAP net income for the first quarter was $3.3 million or $0.06 per diluted share compared to $0.24 per diluted share in the prior quarter and $0.15 per diluted share in the first quarter of 2025. Cash flow from operations for the first quarter was $20.0 million.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results.

Nerdy Inc. (NYSE: NRDY) today announced financial results for the first quarter ended March 31, 2026.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates.

The Trade Desk, Inc. (“The Trade Desk,” the “Company” or “we”) (NASDAQ: TTD), a provider of a global technology platform for buyers of advertising, today announced financial results for its first quarter ended March 31, 2026.